Clinical Efficacy of Cyberknife Combined with TACE for Primary Liver Cancer and the Effect on Immune Function and Tumor Marker Levels
Objective To investigate the clinical efficacy of cyberknife combined with transcatheter arterial chemoembo-lization(TACE)in the treatment of primary liver cancer and the effects on immune function and tumor marker levels.Methods 92 patients with primary liver cancer were selected,and the patients were randomly divided into the observation group(46 cases)and the control group(46 cases).The observation group received cyberknife combined with TACE treatment,and the control group received TACE treatment.The immune function[immunoglobulin A(Ig)A,IgG,IgM],tumor marker levels[alpha-fetoprotein(AFP),γ-glutamyl transpeptidase Ⅱ(GGT-Ⅱ),protein induced by vitamin K absence or antagonist-Ⅱ(PIVKA-Ⅱ)],liver function[alanine aminotransferase(ALT),albumin,total bilirubin(TBIL)]of the 2 groups were compared before and after treat-ment.The clinical efficacy and adverse reactions were compared between the 2 groups.Results After treatment,serum IgA,IgG and IgM levels increased in both groups(P＜0.05),and the observation group was higher than the control group(P＜0.05).Af-ter treatment,serum AFP,PIVKA-Ⅱ and GGT-Ⅱ levels in the 2 groups were decreased(P＜0.05),and the observation group was lower than the control group(P＜0.05).After treatment,the levels of serum ALT and TBIL levels in 2 groups were decreased(P＜0.05),and the observation group was lower than the control group(P＜0.05).The levels of serum albumin levels were in-creased(P＜0.05),and the observation group was higher than the control group(P＜0.05).The effective rate of observation group was higher than that of control group(P＜0.05).There was no difference in the incidence of adverse reactions between the 2 groups(P＞0.05).Conclusion Cyberknife combined with TACE for primary liver cancer can effectively improve patients'im-mune function,liver function and inhibit the expression of tumor markers,the curative effect is better.
万方数据
维普
